Q-omics provides the consensus-scored DDRGK1 profile across patient tissues and cancer cell-line models. DDRGK1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, DDRGK1 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, DDRGK1 protein abundance shows 18,369 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UVM, COAD, and PDAC as cancer lineages where DDRGK1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DDRGK1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DDRGK1 survival associations across molecular data types. DDRGK1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DDRGK1 RNA expression–survival associations across cancer types. High DDRGK1 expression shows unfavorable associations in UVM, LGG, UCS, COAD and TGCT, but favorable associations in STAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for DDRGK1 RNA expression.
This table summarizes DDRGK1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for DDRGK1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DDRGK1 shows higher tumor expression in COAD, KIRC, STAD, LIHC, HNSC and BLCA. The COAD box plot shows higher DDRGK1 RNA expression in tumor versus normal tissue (log2 FC = +0.814, t-test p < 0.001).
This table shows molecular features associated with DDRGK1 in patient tissues and cancer cell lines. In patient samples, DDRGK1 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, DDRGK1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and URINARY_TRACT.
